Citius Oncology (CTOR) Gross Margin (2025 - 2026)
Citius Oncology's (CTOR) quarterly Gross Margin came in at 80.27% in Q1 2026, little changed on a QoQ basis from 79.99% in Q4 2025.
Citius Oncology (CTOR) Gross Margin (2025 - 2026) Analysis & Trends
Citius Oncology (CTOR) has 2 years of Gross Margin data on file, last reported at 80.27% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Citius Oncology | 58.02 Mn | 58.02 Mn | 1.34 Mn | 80.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.27% |
| Dec 31, 2025 | 79.99% |